Diabetes and obesity are not just health issues; they're financial burdens too.
While medication costs grab headlines, they're often less than 10% of the total expense.
Take chronic kidney diseaseour data shows that for those with type 2 diabetes using Simic, there's a 24% reduced risk of developing it.
Did you know a quarter of all Medicare costs go to people with kidney disease?
How do you think we can better manage the broader costs associated with these diseases?
Lars Fruergaard Jrgensen, President and Chief Executive Officer of Novo Nordisk, based in Bagsvrd, Denmark, testified before the Senate HELP Committee to address the question: Why is Novo Nordisk charging Americans with diabetes and obesity outrageously high prices for Ozempic and Wegovy?
